The additional safety and efficacy data for REC-4881 from the TUPELO Phase 1b/2 study, expected in December 2025, could impact the previously reported 43% polyp reduction results in several ways.1 The initial 43% median reduction in polyp burden was preliminary data, presented on May 4, 2025, and was based on a small sample size of six patients at the week 13 assessment.1
Here's a breakdown of potential effects:
- Confirmation and Strengthening: If the additional data, likely from a larger patient cohort or longer follow-up, shows similar or improved efficacy, it would strengthen confidence in REC-4881's potential. This could validate the initial promising signal and potentially lead to further advancement of the program.
- Dilution or Weakening: Conversely, with a larger dataset, the median reduction might decrease. Clinical trial results, especially preliminary ones from small sample sizes, are subject to change as more patient data becomes available.2 Factors such as variability in patient response, inclusion of patients with different disease severities, or longer treatment durations could influence the overall median. For instance, the initial data noted that while five of six patients experienced reductions, one patient showed a substantial increase from baseline.1
- Statistical Significance: The new data will be crucial in determining the statistical significance of the observed polyp reduction. A larger sample size can provide more robust statistical power, which is essential for regulatory evaluation and investor confidence.
- Safety Profile: The additional 2H25 data will also include updated safety information.1 While the early safety profile was generally consistent with other MEK1/2 inhibitors, with most adverse events being Grade 1 or 2, and Grade 3 events in 16% of patients, a larger dataset could reveal less common or more severe adverse events, or confirm the favorable safety profile.3
- Subgroup Analysis: More data may allow for subgroup analyses, identifying specific patient populations that respond better or worse to REC-4881, which could refine the drug's target indication.
- Impact on Spigelman Stage: The initial data also reported that 50% of patients (3 out of 6) achieved a ≥1-point improvement in Spigelman stage, a measure of upper GI disease severity.1 Additional data will show if this trend continues or improves.
It is important to remember that preliminary or interim data, as was the case with the May 2025 results, remains subject to audit and verification procedures, and final data can materially differ.2 Investors and analysts will closely scrutinize the December 2025 data release for consistency, statistical significance, and any changes to the safety profile, as these will be critical in assessing REC-4881's future prospects in treating Familial Adenomatous Polyposis (FAP).
For more detailed information on Recursion Pharmaceuticals' pipeline and upcoming catalysts, you can refer to their SEC filings on Fintel, such as their 10-Q from May 5, 2025, and corporate presentations.4
